Lawsuit Follows FDA Warning, IBRX Plunges 21%

What happened

ImmunityBio now faces a securities class action lawsuit after the FDA issued a warning letter in March for misleading promotional claims about Anktiva's efficacy. The lawsuit covers investors who bought between January 19 and March 24, 2026, and the stock dropped 21% on the news, wiping out $2 billion in market cap. This legal action reinforces the regulatory overhang from the FDA's Office of Prescription Drug Promotion, which had already flagged the company's aggressive marketing. While Q1 2026 net product revenue of $44.2 million showed a 15% sequential increase, the new lawsuit introduces additional legal costs and potential settlements that could pressure cash flow. The core thesis of a commercial ramp remains intact, but the risk of regulatory escalation and now litigation has clearly increased.

Implication

The lawsuit materially increases the left-tail risk for IBRX investors, as it could lead to significant legal costs, management distraction, and potential settlement payments that strain the already tight cash position. With $380.9 million in cash and a quarterly operating burn of ~$75.4 million, even a moderate settlement could force dilutive financing. The class action also raises the stakes for the FDA's OPDP investigation, as any admission of misleading claims could be used against the company in court. Investors should wait for at least two quarters of sustained revenue growth above $44 million and a clear resolution of both the OPDP matter and this lawsuit before considering a position. The attractive entry price of $7.00 from the DeepValue report now seems too high given the additional legal uncertainty; a more appropriate entry would be below $5.50, in line with the bear case scenario.

Thesis delta

The thesis shifts from a balanced risk/reward centered on commercial execution and regulatory compliance to one dominated by legal liability. The lawsuit transforms the FDA warning from a contained regulatory issue into a potential cash drain and reputational hit that could delay adoption. The probability of the bear case increases to 40%, while the bull case probability drops to 15%, implying a lower expected value and requiring a higher margin of safety.